The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Dr Swagat Dash, HOD & Senior Consultant, Nuclear Medicine and Molecular Theranostics, Sarvodaya Hospital, Faridabad ...

Pancreatic cancer is frequently a lethal disease with an aggressive tumour biology often presenting with non-specific symptoms. Median survival is approximately 4 months with a 5-year survival of 13%.

well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and ...

The FDA has ap­proved Ex­elix­is’ can­cer drug Cabome­tyx to treat ad­vanced neu­roen­docrine tu­mors in­side and out­side of the pan­creas, mark­ing two new in­di­ca­tions for ...

well-differentiated pancreatic or extra-pancreatic neuroendocrine tumors (pNET or epNET), the FDA said Wednesday. In an interesting and unusual item in Cabometyx’s updated label, the FDA ...

Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors, as shown in the phase 3 CABINET trial. The trial demonstrated a median PFS ...

Cabometyx is approved for treating well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older. The phase 3 CABINET trial showed improved progression-free ...

The study was led by Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine tumors at Dana-Farber Cancer Institute.

Cabozantinib was investigated in both pancreatic and extrapancreatic neuroendocrine tumors. The phase 3 CABINET trial (NCT03375320) was terminated early based on interim outcomes showing benefit of ...